about arsanis

Redefining the Practice of Medicine for Serious Infections


Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections.

Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis’ monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption.

We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.

Arsanis was co-founded in 2010 by three infectious disease and industry veterans:

  • Eszter Nagy, MD, PhD
  • Tillman U. Gerngross, PhD, Chairman of the Arsanis Board of Directors and CEO of Adimab; and
  • Errik B. Anderson, venture capitalist and President and Chief Operating Officer of Compass Therapeutics.

Learn more about our programs and pipeline of novel targeted mAbs.

management team



    Michael Gray, MBA, CPA

    President, Chief Executive Officer and Chief Financial Officer

    Michael Gray, MBA, CPA, has nearly 20 years of industry business development and financial leadership experience, including financial strategy, planning, and operations.

    Prior to Arsanis, Mr. Gray spent 15 years in leadership positions at Curis, Inc., a publicly-held oncology drug development company, including Chief Financial Officer, Chief Business Officer, and Chief Operating Officer. He was instrumental in financial and business development transactions that raised over $350 million for the company, including partnering, equity, and debt transactions. Previously, Mr. Gray held positions including Controller and de facto Chief Financial Officer of Reprogenesis, a biotechnology company focused on the development of cell therapy drug candidates. Mr. Gray has also served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP.

    Mr. Gray holds an active Certified Public Accountant license (Rhode Island). He earned his MBA in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and a Bachelor of Science in Accounting from Bryant College.


    David Mantus, PhD

    Chief Development Officer, and Managing Director of Arsanis Biosciences GmbH

    David Mantus, PhD, has more than 24 years of drug development experience, including clinical, regulatory, and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious diseases. His work in infectious disease product development has included small molecules, microbiome-based therapeutics, immune globulins, monoclonal antibodies, and vaccines. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis, he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, PAREXEL, and Procter & Gamble Pharmaceuticals. Previously, Dr. Mantus was a Postdoctoral Research Fellow in Biomedical Engineering at the University of Washington and Associate Professor of Pharmaceutical Sciences at MCPHS University. He is co-author of a book on regulatory affairs entitled, FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics,that is currently in its third edition.

    Dr. Mantus received his Master of Science and PhD in Chemistry from Cornell University.

    board of directors


    Tillman U. Gerngross, Chairman

    Co-Founder and CEO, Adimab; Venture Partner, SV Life Sciences

    Chip Clark

    President and CEO, Genocea Biosciences, Inc.

    Carl Gordon

    Partner, OrbiMed Advisors

    Michael Gray

    President, CEO and CFO

    David McGirr

    Biotechnology Company Board Member

    Terry McGuire

    Founding Partner, Polaris Partners

    Claudio Nessi

    Managing Partner, NeoMed

    Michael Ross

    Managing Partner, SV Life Sciences

    René Russo

    Board Member

    Amy Schulman

    CEO, Arsia Therapeutics, President and CEO, Lyndra; Venture Partner, Polaris Partners

    scientific advisory board


      The Arsanis Scientific Advisory Board members are international infectious diseases experts. They collectively hold extensive research, clinical and drug development expertise in anti-infectives, respiratory disease, intensive care unity medicine, and antibody engineering.

      Paul G. Ambrose, PharmD

      Paul G. Ambrose, PharmD, is President of the Institute for Clinical Pharmacodynamics, New York, USA; Honorary Research Fellow in Infectious Diseases at the University of Oxford, UK; and Adjunct Associate Research Professor at the University at Buffalo, New York. Dr. Ambrose brings translational expertise in the application of pharmacokinetic-pharmacodynamic principles, with research focusing on anti-infective translational science. Dr. Ambrose is the author of over 120 peer-reviewed scientific publications.

      Birgitta Henriques-Normark, MD, PhD

      Birgitta Henriques-Normark, MD, PhD, is a Professor in medical microbial pathogenesis in the Department of Microbiology, Tumor, and Cell Biology at the Karolinska Institutet, as well as a Medical Doctor (MD) with a specialty in clinical bacteriology. Professor Henriques-Normark has extensive research and clinical expertise in host-bacterial interactions, ranging from bacterial regulatory systems to the immune response of the host, especially in the field of respiratory pathogens, mainly Streptococcus pneumoniae. Dr. Henriques-Normark has authored or co-authored more than 157 publications.

      Rick Malley, MD

      Rick Malley, MD, is Kenneth McIntosh Chair in Pediatric Infectious Diseases at Children’s Hospital Boston and an Associate Professor of Pediatrics at Harvard Medical School. Besides being an active pediatric infectious disease clinician, his research laboratory focuses on pneumococcal pathogenesis and disease prevention with emphasis on correlates of protection and novel immune approaches based on vaccination. Dr. Malley has authored or co-authored 80 scientific publications in the field of infectious diseases.

      Howard Mayer, MD

      Howard Mayer, MD, is Senior Vice President and Head of Global Clinical Development at Shire. Previously, Dr Mayer was Chief Medical Officer at EMD Serono, Head of Clinical Development and Medical Affairs for Virology at Pfizer leading the clinical development program of Selzentry, a novel oral entry inhibitor for the treatment of HIV/AIDS, and has worked on antibacterial drug development at Bristol-Myers Squibb. With Dr. Mayer’s extensive clinical and commercial expertise in anti-infective drug development, he was recognized in 2011 as one of PharmaVoice’s 100 Most Inspiring People in the Life Sciences Industry. Dr. Mayer has authored more than 70 publications and abstracts.

      Steven M. Opal, MD

      Steven M. Opal, MD, is Professor of Medicine in the Infectious Disease Division at The Warren Alpert Medical School of Brown University and Chief of Infectious Disease Division at Memorial Hospital of Rhode Island. Dr. Opal’s pivotal contributions to the infectious disease field include research on the patho-mechanism of septic shock, host-pathogen interaction in systemic infection, and antibiotic resistance; and clinical trial design, implementation, and analysis of data from Phase 1 to Phase 3 studies. He is the editor of several academic research journals and textbooks and the chair of the International Sepsis Forum.

      Claire Poyart, MD, PhD

      Claire Poyart, MD, PhD, is Professor of Medical Microbiology, University Paris Descartes, and Head of the Laboratory of Bacteriology of Cochin Hospital Head of the National Reference Centre for Streptococci in France. As a clinical microbiologist, her clinical research focuses on the epidemiological characterization of Group B Streptococcus and the development of diagnostic tools for the detection and the identification of Gram-positive bacteria. Her basic research is directed towards characterizing streptococcal virulence and resulted in major contribution to the molecular understanding of the Group B Streptococcus disease mechanism. Dr. Poyart has authored and co-authored over 100 scientific publications in the fields of clinical microbiology and infectious diseases.

      Antoni Torres, MD, PhD, FERS

      Antoni TorresMD, PhD, FERS, is an internally recognized expert in ICU clinical medicine and respiratory disease. Professor Torres is Head of the Respiratory Intensive Care Unit, Department of Pneumology and Respiratory Allergy, Clinical Institute of the Thorax, Hospital Clinic of Barcelona and Coordinator of all the ICUs of the Clinic Thorax Institute. Professor Torres is also Professor of Medicine at Faculty of Medicine at the University of Barcelona, has authored or co-authored more than 350 original articles, and has coordinated or directed many research projects in the area of respiratory disease.

      Richard Wunderink, MD

      Richard Wunderink, MD, is Professor of Medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and Medical Director of the Medical Intensive Care Unit, Northwestern Memorial Hospital. Professor Wunderink has specialty expertise in the areas of sepsis and pulmonary infections, especially ventilator-associated pneumonia and community-acquired pneumonia. Dr. Wunderink has authored or co-authored over 230 publications.

      clinical advisory board


        Marin Kollef, MD, FACP, FCCP, Chairman

        Marin Kollef, MD, FACP, FCCP, Chairman, is Professor of Medicine at the Washington University School of Medicine and Director of the Medical Intensive Care Unit and Respiratory Care Services at Barnes-Jewish Hospital in St. Louis, Missouri.

        Paul G. Ambrose, PharmD

        Paul G. Ambrose, PharmD, is President of the Institute for Clinical Pharmacodynamics, New York, USA; Honorary Research Fellow in Infectious Diseases at the University of Oxford, UK; and Adjunct Associate Research Professor at the University at Buffalo, New York. Dr. Ambrose brings translational expertise in the application of pharmacokinetic-pharmacodynamic principles, with research focusing on anti-infective translational science. Dr. Ambrose is the author of over 120 peer-reviewed scientific publications.

        Philip S. Barie, MD

        Philip S. Barie, MD, is Professor of Surgery at Weill Cornell Medical College and an attending surgeon at New York-Presbyterian/Weill Cornell Medical Center. He is also Chief, Preston A. Wade (Red) Acute Care Surgery Service, New York-Presbyterian Hospital, Weill Cornell Medical Center.

        Helen W. Boucher, MD

        Helen W. Boucher, MD, is Director of the Infectious Diseases Fellowship Program and Ventricular Assist Device and Cardiac Transplant Infectious Diseases Program at Tufts Medical Center. She is an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center and Associate Professor of Medicine at Tufts University School of Medicine.

        Jean Chastre, MD

        Jean Chastre, MD, is a Consulting Professor, Medical ICU, Hospital Pitié-Salpêtrière, Paris.

        Ralph Corey, MD

        Ralph Corey, MD, is Professor of Medicine, Infectious Disease, and Pathology; Gary Hock Professor of Global Health; and Vice-Chairman of the Department of Medicine at Duke University.

        Vance Fowler, MD

        Vance Fowler, MD, is Professor of Medicine and Professor in Molecular Genetics and Microbiology at Duke University.

        Bruno Francois, MD

        Bruno Francois, MD, is Specialist, Intensive Care Medicine at University Hospital of Limoges, France. Dr. Francois is also Head of the Limoges Clinical Investigational Center.

        Howard Mayer, MD

        Howard Mayer, MD, is Senior Vice President and Head of Global Clinical Development at Shire Pharmaceuticals.

        Vandana Menon, MD, PhD, MPH

        Vandana Menon, MD, PhD, MPH, is Vice President, Better Outcomes Corporation and Adjunct Associate Professor, Tufts-New England Medical Center.

        Debra Poutsiaka, MD, PhD

        Debra Poutsiaka, MD, PhD, is Associate Professor of Medicine, Tufts University School of Medicine and an Attending Physician, Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center.

        George Sakoulas, MD

        George Sakoulas, MD, is Associate Adjunct Professor, Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection, and Inflammation, at the University of California San Diego School of Medicine.

        Joseph Solomkin, MD

        Joseph Solomkin, MD, is Professor of Surgery (Emeritus), University of Cincinnati College of Medicine and the CEO of OASIS Global.

        George Talbot, MD

        George Talbot, MD, is a Member and Immediate past Co-Chair of the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. Dr. Talbot is a Principal at Talbot Advisors, LLC.

        Antoni Torres, MD, PhD

        Antoni Torres, MD, PhD, is Head, Respiratory Intensive Care Unit, Department of Pneumology and Respiratory Allergy at the Clinical Institute of the Thorax, Hospital Clinic of Barcelona.

        financing and partnerships



        Arsanis has successfully raised capital from top-tier life science investors OrbiMed, Polaris Ventures, SV Life Sciences, NeoMed, EMBL Ventures, The Bill & Melinda Gates Foundation, and GV, securing $90M since 2010.



        Arsanis has also entered into multiple collaborations with leading industry, academic, and clinical research groups, building relationships with global leaders in the fields of antibody discovery and infectious diseases.

        Arsanis’ lead clinical candidate, ASN100, and human mAbs in several pre-clinical programs (ASN400 and ASN500), were discovered in collaboration with Adimab, LLC, utilizing their industry premier human antibody discovery and optimization platform.